HEXADROL Drug Patent Profile

Which patents cover Hexadrol, and what generic alternatives are available?

Hexadrol is a drug marketed by Aspen Global Inc and is included in three NDAs.

The generic ingredient in HEXADROL is dexamethasone sodium phosphate. There are thirty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the dexamethasone sodium phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hexadrol

A generic version of HEXADROL was approved as dexamethasone sodium phosphate by HIKMA on September 7^th, 1982.

Summary for HEXADROL

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	165
Patent Applications:	5,968
DailyMed Link:	HEXADROL at DailyMed

Recent Clinical Trials for HEXADROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 2
Southwest Oncology Group	Phase 3
University of Southern California	Phase 1/Phase 2

See all HEXADROL clinical trials

US Patents and Regulatory Information for HEXADROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aspen Global Inc	HEXADROL	dexamethasone	ELIXIR;ORAL	012674-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Aspen Global Inc	HEXADROL	dexamethasone	TABLET;ORAL	012675-009	Approved Prior to Jan 1, 1982		DISCN	No	No
Aspen Global Inc	HEXADROL	dexamethasone sodium phosphate	INJECTABLE;INJECTION	014694-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Aspen Global Inc	HEXADROL	dexamethasone	TABLET;ORAL	012675-010	Approved Prior to Jan 1, 1982		DISCN	No	No
Aspen Global Inc	HEXADROL	dexamethasone sodium phosphate	INJECTABLE;INJECTION	014694-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Aspen Global Inc	HEXADROL	dexamethasone sodium phosphate	INJECTABLE;INJECTION	014694-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Aspen Global Inc	HEXADROL	dexamethasone	TABLET;ORAL	012675-007	Approved Prior to Jan 1, 1982		DISCN	No	No

EU/EMA Drug Approvals for HEXADROL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

HEXADROL: Market Dynamics and Financial Trajectory Analysis

Last updated: April 7, 2026

What is HEXADROL?

HEXADROL is the brand name for methylprednisolone sodium succinate, a corticosteroid used mainly for its anti-inflammatory and immunosuppressive effects. It treats conditions such as allergic reactions, autoimmune diseases, and certain inflammatory disorders. The drug is available in injectable forms and is commonly used in hospital settings.

Market Overview

Global Market Size and Growth

The global corticosteroids market, which includes drugs like HEXADROL, is valued at approximately \$5.3 billion in 2022. It is projected to grow at a CAGR of 4.5% between 2023 and 2030, driven by increasing prevalence of autoimmune and inflammatory conditions and expanded hospital utilization.

Year	Market Size (USD billion)	CAGR (2023-2030)
2022	5.3	—
2025	6.3	4.3%
2030	7.6	4.5%

Key Regional Markets

• North America: Dominates with over 40% market share. High prevalence of autoimmune diseases and widespread hospital use.
• Europe: Holds roughly 25% market share, benefiting from aging populations and healthcare investments.
• Asia-Pacific: Fastest growth rate of approximately 6% CAGR, driven by increasing healthcare infrastructure and rising incidence of autoimmune and inflammatory diseases.

Competitive Landscape

Major pharmaceutical firms supplying methylprednisolone products include Pfizer, Sandoz (Novartis), and Teva. Generic formulations account for approximately 70% of the market, with branded products holding the remaining share.

Regulatory and Patent Landscape

Patent Expiry and Generic Entry

• The original patent for methylprednisolone formulations expired in 2010.
• Numerous generic versions entered the market post-patent expiry.
• No recent patents restrict the entry of biosimilars or new formulations of HEXADROL.

Regulatory Trends

• The FDA approved expanded indications for methylprednisolone in 2018.
• European Medicines Agency (EMA) has granted orphan drug status for specific formulations.

Financial Trajectory Analysis

Sales Performance

• 2022: Estimated global sales of HEXADROL and its analogs sum to \$950 million.
• 2023-2025: Anticipated annual growth of approximately 5-6%, considering market expansion and increased use in COVID-19 related treatments.
• 2026-2030: Growth stabilizes around 4%, with increased competition from biosimilars and evolving treatment guidelines.

Price Trends

• Market competition has driven prices downward.
• Average wholesale price (AWP) for a 40 mg vial declined approximately 20% over the past five years.
• Price erosion is expected to continue, impacting profit margins for branded formulations.

Revenue Drivers

• Rising adoption in emerging markets.
• Expansion into new indications, including acute respiratory distress syndrome.
• Growth of hospital-administered treatments during pandemics or similar health crises.

Challenges and Opportunities

Challenges

• Patent expiration leading to generic competition.
• Price pressures from healthcare systems emphasizing cost containment.
• The emergence of biosimilar methylprednisolone products.

Opportunities

• Developing new formulations with extended-release or improved bioavailability.
• Entering markets with unmet needs, such as small-volume injectables for outpatient therapy.
• Combining HEXADROL with innovative drug delivery systems for better efficacy and compliance.

Key Market Players and Recent Developments

Company	Strategic Moves	Products/Focus
Pfizer	Expanded access in emerging markets	Methylprednisolone injection
Sandoz (Novartis)	Launch of biosimilar methylprednisolone	Biosimilars and generics
Teva	Focused on cost-efficient formulations	Generic methylprednisolone

Future Outlook

• The market will continue to grow driven by increasing demand in emerging markets and expanding indications.
• Price competition will intensify, pressuring margins.
• Innovation in drug delivery and biosimilar development will influence market dynamics.

Key Takeaways

• The global corticosteroids market, inclusive of HEXADROL, is projected to reach \$7.6 billion by 2030.
• Growth primarily stems from healthcare infrastructure expansion in Asia-Pacific and aging European populations.
• Patent expiries and biosimilar competition will reduce revenue streams for branded products, impacting overall profitability.
• Continued clinical approval of new indications and formulation innovations offer room for growth.
• Market pricing trends favor generic and biosimilar entries, pressuring branded product margins.

FAQs

1. What is the primary therapeutic use of HEXADROL?
It treats inflammatory and autoimmune conditions, including allergic reactions, multiple sclerosis exacerbations, and certain post-transplant immunosuppressive protocols.

2. How does patent expiry affect HEXADROL’s market?
Patent expiry enables generic manufacturers to enter the market, increasing competition and lowering prices, which reduces revenue for original branded products.

3. What are the main competitors to HEXADROL?
Generic methylprednisolone formulations from multiple manufacturers, biosimilars from Novartis (Sandoz), and branded drugs from Pfizer.

4. How does vaccination and pandemic management influence HEXADROL sales?
Increased hospital demand during COVID-19 and associated respiratory treatments temporarily raised sales. Long-term effects depend on clinical guidelines and competition.

5. What innovations could reshape HEXADROL's market position?
Development of extended-release formulations, improved delivery methods, and new indications through clinical trials could expand revenue streams.

---

References

[1] MarketsandMarkets. (2022). Corticosteroids Market Size, Share & Trends Analysis.
[2] Grand View Research. (2023). Global Corticosteroids Market Report.
[3] U.S. Food and Drug Administration. (2018). Expanded Indications for Methylprednisolone.
[4] European Medicines Agency. (2021). Regulatory Guidelines for Corticosteroid Formulations.
[5] IMS Health. (2022). Pharmaceutical Market Data.